NCT01006629 - Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

July 31, 2010

Conditions

Respiratory Syncytial Virus InfectionPremature BirthBronchopulmonary DysplasiaCongenital Heart Disease

Interventions

BIOLOGICAL

palivizumab

palivizumab 15 mg/kg intramuscularly

Trial Locations (19)

117198

Site Ref # / Investigator 24022, Moscow

117931

Site Ref # / Investigator 15744, Moscow

117997

Site Ref # / Investigator 15745, Moscow

Site Ref # / Investigator 24025, Moscow

119991

Site Ref # / Investigator 15781, Moscow

Site Ref # / Investigator 22686, Moscow

125412

Site Ref # / Investigator 15747, Moscow

153731

Site Ref # / Investigator 22699, Ivanovo

193312

Site Ref # / Investigator 22692, Saint Petersburg

194100

Site Ref # / Investigator 22683, Saint Petersburg

194291

Site Ref # / Investigator 22693, Saint Petersburg

196650

Site Ref # / Investigator 22685, Saint Petersburg

197022

Site Ref # / Investigator 15722, Saint Petersburg

198205

Site Ref # / Investigator 15748, Saint Petersburg

Site Ref # / Investigator 15782, Saint Petersburg

420012

Site Ref # / Investigator 22694, Kazan'

630091

Site Ref # / Investigator 22696, Novosibirsk

Site Ref # / Investigator 24023, Novosibirsk

634012

Site Ref # / Investigator 15746, Tomsk